Review
Copyright ©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 7, 2007; 13(5): 657-670
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.657
Table 1 Previous published human studies on the results of ischaemic preconditioning following liver resection and transplantation
Study groupSample1SurgeryIPC2Ischaemia and reperfusion time (min)3Parameters assessedOutcome of IPC
Clavien et al[17] (2000)24 (12)Liver resection10I + 10RIPC and control (TI: 30)PT, Bilirubin, ALT, AST, Histology, Caspase-3 and 8 activity, SEC apoptosis, Blood loss, Transfusion, ITU stay, LOSProtective against IRI Beneficial in patients with steatosis
Clavien et al[204] (2003)100 (50)Liver resection10I + 10RIPC (TI: 36 ± 5.9, Op: 225 ± 73), Control (TI: 35 ± 6.8, Op: 240 ± 92)PT, Bilirubin, ALT, AST, Histology, Hepatic ATP, Blood loss, Transfusion, ITU stay, LOSProtective against IRI Beneficial in younger patients, those with steatosis and longer periods of occlusion
Li et al[205] (2004)29 (14)Liver resection5I + 5RIPC (TI: 18 ± 3.6, Op: 191.3 ± 74.9), Control (TI: 17.4 ± 2.3, Op: 208.2 ± 45.3)Bilirubin, ALT, AST, Histology, Caspase-3 activity, SEC apoptosis, LOSProtective against IRI, mainly HCC patients with cirrhosis Shorter hospital stay
Nuzzo et al[209] (2004)42 (21)Liver resection10I + 10RIPC (TI: 54 ± 19, Op: 321 ± 92), Control (TI: 36 ± 14, Op: 339 ± 112)PT, Bilirubin, ALT, AST, Transfusion, Morbidity, MortalityReduces operative bleeding Protective against IRI
Chouker et al[206] (2004)68 (22)Liver resection10I + 10RIPC (TI: 32 ± 6.3, Op: 251 ± 46), Control without PR (TI: NA, Op: 52 ± 30), Control with PR (TI: 35 ± 11, Op: 257 ± 83)ALT, AST, Fluid loss, Transfusion, 4Cardiovascular statusProtective against IRI Improves haemodynamic stability
Chouker et al[207] (2005)75 (25)Liver resection10I + 10RIPC (TI: 35.5 ± 2.7, LR: 32.2 ± 2.0), Control without PR (TI: NA, LR: 39 ± 4.5), Control with PR (TI: 35.6 ± 2.6, LR: 33.2 ± 2.3)IL-6, IL-8, Cytochrome c, Adhesion molecules [B2-integrins (CD18)], Histology (neutrophil infiltration)Protective against IRI by attenuating neutrophil activation and IL-8 release
Chouker et al[208] (2005)73 (25)Liver resection10I + 10RIPC (TI: 35.12 ± 13.6, LR: 31.50 ± 9.1), Control without PR (TI: NA, LR: 34.77 ± 16.5), Control with PR (TI: 34.2 ± 10.9, LR: 32.13 ± 10)PT, ALT, AST, α-GSTProtective against IRI Prevented early rise of α-GST
Koneru et al[210] (2005)62 (34)Transplant5I + 5RIPC (CI: 384 ± 92, WI: 41 ± 5.8), Control (CI: 415 ± 87, WI: 37 ± 5.6)INR, Bilirubin, ALT, AST, Histology (apoptosis, hepatocyte swelling), LOS, Survival (6 mo)No beneficial effect
Azoulay et al[212] (2005)91 (46)Transplant10I + 10RIPC (CI: 436 ± 116, Op: 441 ± 119), Control (CI: 461 ± 96, Op: 462 ± 98)PT, Bilirubin, ALT, AST, Histology, Graft function, Morbidity, MortalityBetter ischaemic tolerance Decreased early graft function
Jassem et al[211] (2005)23 (9)Transplant10I + 10RIPC (CI: 620 ± 190, WI: 43.9 ± 13), Control (CI: 665 ± 280, WI: 40.4 ± 9)AST, INR, Lactate, ITU stay, Histology (neutrophil infiltration, platelet deposition), Graft functionProtective against IRI Reduces inflammatory response Shorter ITU stay
Cescon et al[213] (2006)47 (23)Transplant10I + 15R5IPC [TI: 388 (259-830), Op: 440 (225-725)], Control [TI: 383 (279-695), Op: 465 (280-1015)]PT, Bilirubin, ALT, AST, Histology (neutrophil, lymphocyte infiltration, iNOS, apoptosis), Graft function, Survival (1 yr)Protective against IRI No clinical benefit